We do this all the time. We pay them for their time. Sometimes they do conference calls. Sometimes they prepare slide shows.

Approximately 50% of the cases are filed in the federal court, where standards for scientific evidence are far more rigorous.

Based on improving new product visibility, benefits from restructuring initiatives, and near-term volume boost from Medicare Part D supports our Attractive rating for the U.S. pharmaceutical sector.

Recent launches have significantly larger commercial potential than the previous cycle?and [are] likely to drive improving growth prospects post-2006.

In addition, we think completion of the company's consent decree obligations is a major psychological positive that could also have financial implications, as spending on consultants and inspections declines.

This is in response to a very challenging environment. I would expect broader cuts to be announced within the sales force, marketing, general and (administration) as well as R&D over the longer run.